dc.contributor.author | Bilir, Cemil | |
dc.contributor.author | Durak, Serdar | |
dc.contributor.author | Kızılkaya, Bayram | |
dc.contributor.author | Hacıbekiroğlu, I. | |
dc.contributor.author | Nayir, Erdinç | |
dc.contributor.author | Engin, H. Billur | |
dc.date.accessioned | 2020-12-19T19:48:33Z | |
dc.date.available | 2020-12-19T19:48:33Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Bilir, C., Durak, S., Kızılkaya, B., Hacıbekiroglu, I., Nayır, E., & Engin, H. (2017). Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status. Current oncology (Toronto, Ont.), 24(3), e199–e204. https://doi.org/10.3747/co.24.3486 | en_US |
dc.identifier.issn | 1198-0052 | |
dc.identifier.uri | https://doi.org/10.3747/co.24.3486 | |
dc.identifier.uri | https://hdl.handle.net/11436/2110 | |
dc.description | WOS: 000404547500006 | en_US |
dc.description | PubMed: 28680287 | en_US |
dc.description.abstract | Background Metronomic chemotherapy-administration of low-dose chemotherapy-allows for a prolonged treatment duration and minimizes toxicity for unfit patients diagnosed with advanced non-small-cell lung cancer (NSCLC). Methods Oral metronomic vinorelbine at 30 mg thrice weekly was given to 35 chemotherapy-naive patients who were elderly and vulnerable to toxicity and who had been diagnosed with advanced nsclc. Results Median age in this male-predominant cohort (29: 6) was 76 years (range: 65-86 years). Histology was squamous cell carcinoma in 21 patients and adenocarcinoma in 14. There were no complete responses and 9 partial responses, for an overall response rate of 26%. Stable disease was seen in 15 patients (43%), and 11 patients (31%) had progressive disease. the 1-year survival rate was 34%, and the 2-year survival rate was 8%. the survival analysis showed a median progression-free survival duration of 4 months (range: 2-15 months) and an overall survival duration of 7 months (range: 3-24 months). Conclusions Metronomic vinorelbine had an acceptable efficacy and safety profile in elderly patients with multiple comorbidities who had been diagnosed with advanced nsclc. Metronomic vinorelbine could be a treatment option for elderly patients with poor performance status who are unfit for platinum-based chemotherapy and intravenous single-agent chemotherapy, and who are not candidates for combination modalities. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Multimed Inc | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Metronomic vinorelbine | en_US |
dc.subject | Non-small-cell lung cancer | en_US |
dc.subject | Poor performance status | en_US |
dc.title | Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status | en_US |
dc.type | article | en_US |
dc.contributor.department | RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.contributor.institutionauthor | Durak, Serdar | |
dc.contributor.institutionauthor | Kızılkaya, Bayram | |
dc.identifier.doi | 10.3747/co.24.3486 | |
dc.identifier.volume | 24 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | E199 | en_US |
dc.identifier.endpage | E204 | en_US |
dc.ri.edit | oa | en_US |
dc.relation.journal | Current Oncology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |